Mesoblast Limited (ASX:MSB)
Mesoblast Limited (ASX:MSB) is a world leader in developing innovative cellular medicines. The Company has established what it believes is the industry’s most clinically advanced and diverse portfolio of cell-based product candidates with three programs in Phase 3 clinical studies.
Consistent and durable clinical outcomes have been demonstrated across multiple difficult-to-treat diseases. Its lead product candidates under investigation are:
- MSC-100-IV for acute graft versus host disease
- MPC-150-IM for advanced heart failure
- MPC-06-ID for chronic low back pain due to disc degeneration
- MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy
Mesoblast is also listed on the Nasdaq (NASDAQ:MESO) and has a Level 3 American Depositary Receipt program facility.